STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Erasca reported that ERAS‑0015 caused tumor shrinkage in 40% of advanced pancreatic cancer patients in its early trial.
- ERAS‑0015 achieved a 62% response rate in advanced non‑small cell lung cancer, which Erasca’s CEO called more definitive.
- Revolution Medicines’ daraxonrasib recently doubled overall survival in advanced pancreatic cancer, providing a benchmark for Erasca’s results.
- Jonathan Lim highlighted that the trial combined data from the U.S. and China, underscoring cross‑border development.
Why it matters: Erasca gains a therapeutic edge as 40% of pancreatic and 62% of lung cancer patients see tumor shrinkage, while patients receive a new option; the US‑China trial accelerates cross‑border biotech partnerships.
Ask SkimNews
